Efficacy endpoints
death
DISEASE PROGRESSION
At the cut-off date on January 10, 2022, the median follow-up was 26.8 (1.6–52.0) months. A total of 30 patients experienced disease progression or death, and 2 patients were still on the treatment. The median PFS was 6.0 (95%CI: 3.8–8.2) months (Fig. 
Kaplan-Meier curves of progression-free survival
Subgroup analysis of progression-free survival (PFS)CI: confidence interval